RecruitingPhase 2NCT07060508

L9LS in Women of Childbearing Potential in Mali

Safety and Efficacy of L9LS, a Human Monoclonal Antibody Against Plasmodium Falciparum, in a Randomized, Double-Blind, Placebo-Controlled Trial of Women of Childbearing Potential (WOCBP) in Mali

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Enrollment

290 participants

Start Date

Jul 22, 2025

Study Type

INTERVENTIONAL

Conditions

Malaria

Summary

Safety and Efficacy of L9LS, a Human Monoclonal Antibody Against Plasmodium falciparum, in a Randomized, Double-Blind, Placebo-Controlled Trial of Women of Childbearing Potential (WOCBP) in Mali

Eligibility

Min Age: 18 YearsMax Age: 49 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Placebo and a biological treatment called Single dose of 1800 mg L9LS SC for people with malaria. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years to 49 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.